Charles Schwab
AEGR

Charles Schwab’s Aegerion Pharmaceuticals AEGR Stock Holding History

Charles Schwab’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-210,628
Closed -$780K – 3181
2016
Q1 		$780K Sell
210,628
-95,703
-31% -$593K ﹤0.01% 2422
2015
Q4 		$3.09M Buy
306,331
+130,622
+74% +$1.57M ﹤0.01% 1830
2015
Q3 		$2.39M Buy
175,709
+78,642
+81% +$1.4M ﹤0.01% 1968
2015
Q2 		$1.84M Buy
97,067
+3,032
+3% +$65.6K ﹤0.01% 2143
2015
Q1 		$2.46M Buy
94,035
+4,760
+5% +$121K ﹤0.01% 1940
2014
Q4 		$1.87M Buy
89,275
+13,310
+18% +$335K ﹤0.01% 2051
2014
Q3 		$2.54M Buy
75,965
+4,713
+7% +$146K ﹤0.01% 1827
2014
Q2 		$2.29M Sell
71,252
-276
-0.4% -$10.3K ﹤0.01% 1914
2014
Q1 		$3.3M Buy
71,528
+3,778
+6% +$222K 0.01% 1646
2013
Q4 		$4.81M Buy
67,750
+2,278
+3% +$174K 0.01% 1287
2013
Q3 		$5.91M Buy
65,472
+11,592
+22% +$983K 0.01% 1032
2013
Q2 		$3.71M Buy
+53,880
New +$2.86M 0.01% 1304

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Charles Schwab's AEGR Position: Q2 2016 in Review

Charles Schwab sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 210,628 shares — an estimated $780K sold.

Charles Schwab first reported a position in AEGR in Q2 2013 and held it in 12 quarters. The position peaked at $5.91M in Q3 2013. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

  • Charles Schwab reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Charles Schwab sold 210,628 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $780K.
  • Charles Schwab first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • Charles Schwab's Aegerion Pharmaceuticals position peaked at $5.91M in Q3 2013.
  • 71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on Charles Schwab's 13F filing for Q2 2016, filed 15 Aug 2016.